ITUS Corp (ITUS) Stock: A Disruptive Force In Cancer Diagnostics And Immunotherapy

Cancer is a devastating illness that affects a large population of patients in the United States. In fact, it is estimated by the National Cancer Institute that in the year 2018 alone, 1.73535 million patients will be diagnosed with cancer and 609,640 Americans will succumb to the ailment. However, thanks to incredible advances in the … Read more

Gilead Sciences (GILD) Stock: Falling Hard On Earnings Miss

Gilead Sciences, Inc. (NASDAQ: GILD) is having an incredibly rough start to the trading session this morning, and for good reason. The company reported its financial results missing the mark and outlining key concerns surrounding its hepatitis C franchise. Of course, this concerned investors, leading to declines in the value of the stock. Today, we’ll … Read more

Sangamo Therapeutics (SGMO) Stock: Rocketing On Collaboration With GILD

Sangamo Therapeutics IncĀ (NASDAQ: SGMO) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced that it has entered into a collaboration agreement, leading to excitement among investors and sending the stock screaming for the top. Today, we’ll talk about the news, what we’re seeing from SGMO … Read more

Gilead Sciences (GILD) Stock: Setting Leadership Position In Stone

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences has been an incredibly interesting stock to watch over the past year or so. The company completely dominates the hepatitis C market. However, for about a year now, there have been several questions surrounding the prices of their lead treatments, Harvoni and Sovaldi. Nonetheless, yesterday, news came out … Read more